S. Cohen
4 Papers
S. Cohen is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
TL;DR: Targeting HER-2/neu may be beneficial for a select group of patients with UPSC, and samples are being evaluated for Herceptin-induced over expression by fluorescence in situ hybridization (FISH) and immunohistochemical analysis.
131
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
Joanne Kotsopoulos,Jacek Gronwald,Tomasz Huzarski,Amber M Aeilts,S. Randall Armel,Beth Y. Karlan,Christian F. Singer,Andrea Eisen,Nadine Tung,Olufunmilayo I. Olopade,Louise Bordeleau,Charis Eng,William D. Foulkes,Susan L. Neuhausen,Carey A. Cullinane,Tuya Pal,Robert Fruscio,Jan Lubinski,Kelly A. Metcalfe,Ping Sun,Steven A. Narod,Georgia L. Wiesner,Aletta Poll,R. Kim,Jeanna McCuaig,Dana Zakalik,Fergus J. Couch,Linda Steele,Howard M. Saal,Edmond G. Lemire,Kim Serfas,Kevin Sweet,Seema Panchal,Christine Elser,Roberta E. Reilly,Joanne L. Blum,Cezary Cybulski,Daniel Rayson,Jeffrey S. Dungan,Stefania Zovato,Antonella Rastelli,Pål Møller,S. Cohen +42 more
TL;DR: Chemoprevention may be an effective risk-reduction option for BRCA mutation carriers, but further studies with longer follow-up are necessary.
12
Activation of the CREB Coactivator CRTC2 by Aberrant Mitogen Signaling promotes oncogenic functions in HPV16 positive head and neck cancer
Miranda B. Carper,Saumya Goel,Anna M Zhang,Jeffrey S. Damrauer,S. Cohen,Matthew P. Zimmerman,Gabrielle M. Gentile,Kshitij Parag-Sharma,Ryan M. Murphy,Kotaro Sato,Kwangok P. Nickel,Randall J. Kimple,Wendell G. Yarbrough,Antonio L. Amelio +13 more
TL;DR: In this paper , the cAMP Regulated Transcription Coactivator 2 (CRTC2) was identified to be overexpressed and constitutively activated in head and neck squamous cell carcinoma (HNSCC) patients.
7
Association of Community Cancer Centers: Institution-Directed Quality Improvement of Genetic Counseling and Testing for Community Oncology Patients with Breast Cancer
Leigh Boehmer,Latha Shivakumar,Julia R. Trosman,Christine B. Weldon,Zohra Ali-Khan Catts,S. Cohen,Jennifer R. Klemp,Charles H. Shelton +7 more
TL;DR: The mean age of patients with BRCA1/2 pathogenic variants who develop breast cancer is considerably lower, compared to the mean age for patients with sporadic breast cancer (42 years vs. 64 years, respectively), which clearly factors into decision making as mentioned in this paper .